

From Evidence to Practice

Principles to Optimize Integration of HER2- and TROP2-Directed ADCs for Advanced Breast Cancer



Sibylle Loibl, MD, PhD



Patrick Neven, MD, PhD

WED
MAY 14

Cristina Saura, MD, PhD

 **ICM-International Congress Center, Munich Messe**
Room 1

 **11:30 AM – 12:30 PM CME Symposium**



ENGAGE IN DISCUSSION WITH THE EXPERTS

- Expanding the Importance of Biomarker Testing in Advanced Breast Cancer Management
- ADC Strategies in Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
- ADC Advancements in HR-Positive, HER2-Low Breast Cancer
- Expanding ADC Options for Triple-Negative Breast Cancer
- Preparing for Complexities in ADC Care: Managing Brain Metastases and Key Adverse Events